SVRA - Savara Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$9.50
DETAILS
HIGH:
$11.00
LOW:
$5.00
MEDIAN:
$10.00
CONSENSUS:
$9.50
UPSIDE:
104.30%
About Savara Inc. (https://www.savarapharma.com)
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Matthew Pauls | Chairman & Chief Executive Officer | 1971 | $975,000 USD |
| Yasmine Wasfi | Chief Medical Officer | – | $681,578 USD |
| Robert Lutz | COO & CFO | 1969 | $665,625 USD |
| Anne Erickson | Chief Business & Corporate Affairs Officer | 1972 | – |
| Brian Maurer | Head of Clinical Operations | – | – |
| Brian Robinson | Executive Vice President of Global Medical Affairs | – | – |
| Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | – | – |
| Kate McCabe | Chief Legal Officer | 1986 | – |
| Megan Carpenter | Chief People Officer | – | – |
| Siddharth J. Advant | Executive Vice President of Global Technical Operations | – | – |